Micro particles levels Increase One Week after New onset of Heart Failure: New Study
Bonn: The level of cell-specific microparticles has increased one week after Transverse aortic constriction (TAC) with a rapid decline thereafter, a new study announced.
The very first systematic study of microparticles' event is published recently in International Journal of Cardiology. The study investigated the effect of TAC-induced heart failure on the level of circulating microparticles in mice. Heart weight/ body weight ratio, end-diastolic diameter, end systolic diameter and fractional shortening were used for monitoring TAC-induced heart failure.
Researchers used flow cytometry for quantification of circulating microparticles in mice following TAC. Both Nano particle Tracking Analysis and immunoblotting for Flotillin-1 were used for characterizing microparticles and later its content was investigated by microRNA analyses.
Important observations of the study include:
- increasing numbers of circulating microparticles in the first week after TAC with a rapid decline thereafter simultaneously.
- Strongest increase was observed for lymphocyte microparticles containing miR-26a-5p and miR-146b-5p.
- The most relevant fraction of circulating Extra Cellular Vesicles after TAC derived from lymphocytes containing has-miR-26a-5p and / -146b-5p which also is known to be involved in inflammatory processes.
The study gives a formerly obscure timely limited occurrence of circulating microparticles after new onset of heart failure containing immune-modulatory miRs. Taking into account that therapeutic strategies are limited and also underlines the significant role of microparticles in an acute heart failure to understand the impact of circulating microparticles on vascular target cells in acute heart failure.
Reference:
The study is published in International Journal of Cardiology titled "Transverse aortic constriction-induced heart failure leads to increased levels of circulating microparticles" November 2021.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.